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Hepatitis C virus infections proceed to chronicity in the majority of cases.  In patients, 
hepatitis C viruses exist as a dynamic and complex quasispecies. The dominant species at 
any one time arises in response to host immune pressure and other, incompletely 
understood factors. It is critical to understand all the mechanisms by which dominance is 
achieved but this is difficult to study in vivo. Therefore, it would be useful to develop a 
cell culture system in which naturally occurring quasispecies could be studied. Hepatitis 
C virus glycoprotein genes E1 and E2 were PCR-amplified as a cassette from the plasma 
of a chronically infected patient and shotgun cloned into a modified 1a/JFH1 infectious 
cDNA clone. Following transformation of bacteria, plasmids were batch-harvested, 
transcribed, and transfected into Huh 7.5 cells to produce a quasispecies of the 
hypervariable region 1 (HVR1) that mimicked that circulating in vivo. Serial passage of 
the quasispecies in vitro resulted in replacement of the initially dominant species with a 
new HVR1 species co-existing with selected growth-enhancing mutations located outside 
of HVR1. Antibody raised against one HVR1 sequence neutralized virus with the 
homologous HVR1 and cross-neutralized virus with a different sequence. Reciprocal 
swapping of the HVR1 regions between the two dominating species demonstrated that 
the HVR1 sequence affects the efficiency of replication and of neutralization by 












Hepatitis C virus is a small, enveloped RNA virus with a positive sense genome 
that encodes non-structural proteins required for replication and/or assembly, a capsid or 
core protein, and two glycoproteins, E1 and E2, that form heterodimers which comprise 
the virus receptor. The virus is a member of the Flaviviridae family, genus Hepacivirus 
(7) and is a significant human pathogen which is transmitted mainly through blood or 
blood products. 170 million people worldwide are infected by HCV and it is the major 
cause of chronic hepatitis: severe sequelae include liver cirrhosis, hepatocellular 
carcinoma and death (10). Presently, antiviral therapy includes interferon and ribavirin 
treatment (13,17) but the efficacy of these drugs varies depending on the genotype of 
HCV, host factors, and treatment dose and schedule (5,8). Unfortunately, side effects of 
drug treatment can be severe. For these reasons, vaccine alternatives to drug treatment 
have been vigorously pursued, but with limited success (15).  
Vaccine development has been stymied by the extreme quasispecies diversity of 
HCV (2). Antibodies to the glycoproteins usually arise in the chronic phase of infection 
and virus persists even in the presence of neutralizing antibodies, presumably because 
neutralization- escape mutants are selected from the vast quasispecies. The hypervariable 
region 1 (HVR1) located at the N-terminus of E2 is the most variable domain in HCV 
and may play a role in immune evasion (3,14). The HVR1 region is thought to be 
involved in cell attachment through interaction with scavenger receptor class B type 1 
(12) ; although antibodies to HVR1 could neutralize virus post-attachment to cultured 
hepatoma  cells, they did not inhibit binding to CD81, another HCV receptor (18) A 
deletion mutant lacking the HVR1 region was viable, although attenuated, in 
chimpanzees (4). Antibodies directed against the HVR1 can neutralize the virus and it has 
been proposed to serve as a decoy to divert the humoral immune response away from 
more critical regions. Recent studies of JFH1-based recombinant viruses lacking HVR1 
suggested that HVR1 shields important conserved neutralization epitopes (9). Until 
recently, studies of HCV replication and neutralization had to be performed in 
chimpanzees but the development of the HCV pseudoparticle system provided a more 
widely available system with which to study virus-cell interactions and neutralization (1). 
Even more useful was the subsequent development of the JFH1 cell culture system since 
this genotype 2a virus strain could complete the entire replication cycle of HCV in vitro 
(19). Although the JFH1 virus remains the only strain to be successfully cultured, 
chimeric viruses which express the structural proteins of the other genotypes from the 
JFH1 backbone were subsequently developed and all are available as infectious cDNA 
clones (6,20). In the current proof-of-principle study, we have explored the possibility of 
utilizing the chimeric genotype 1a/JFH1 cDNA clone to reproduce and study a naturally 













Materials and Methods 
 
Shotgun cloning. Acute phase plasma (40 uL) from patient H, containing 10 6.5   
 50% chimpanzee infectious doses of HCV per mL was extracted with Trizol LS 
(Invitrogen, Carlsbad, CA) and HCV RNA was reverse transcribed with Superscript II 
RTase (Invitrogen). The first step of nested PCR was performed as long PCR (15) with 
KlenTaq enzyme (Clontech, Mountain View, CA) and primers in core and the 3’ UTR as 
described previously (10). Second step PCR used E1- and E2- specific primers. The sense 
primer ( 5'-TGCCCGCTTCAGCCTACCAAGTTCGAAATTCC-3')contained an 
introduced unique Bsp119I restriction site ( bold and underlined )at the 5’ end of E1 and 
the antisense primer (5'-GATGCTGCATTGAGTATTACGAGGTTCTCCAGCGCT-3') 
contained an introduced AfeI restriction site ( bold and underlined) at the 3’ end of E2: 
neither introduced restriction site altered the amino acid sequence. 
The backbone plasmid, a gift from S. Lemon, consisted of the 1a/2a intergenotypic 
chimera H77-NS2/NS3-JFH1/Q125L, a chimera that had been adapted to grow in cell 
culture (20). A naturally-occurring AfeI restriction site was abolished and Bsp119I and a 
new AfeI restriction site were introduced by standard methods at the beginning of E1 and 
the end of E2. Following digestion of the plasmid and the plasma PCR products with 
Bsp119I and AfeI , the two components were purified on agarose gels, ligated together 
and transformed into the JM109 strain (Promega, Fitchburg, WI) of Escherichia coli. 
Individual colonies were picked from one plate for sequencing to determine quasispecies 
distribution, whereas, colonies on a duplicate plate consisting of 115 well-separated 
colonies and about 50 overlapping colonies were batch-harvested as a mixture for 
production of a quasispecies. Primer sequences for plasmid construction or PCR 
amplification are available on request. 
 
Transfection of Huh7.5 cells. The mixture of quasispecies plasmids was linearized with 
XbaI and 50 ug of DNA was transcribed with T7 RNA polymerase (Promega) as 
described previously (10). The RNA reaction mixture was mixed with DMRIE-C 
transfection reagent (Invitrogen) and inoculated onto Huh7.5 cells. Transfected cells were 
grown at 37°C in the CO2 incubator and medium was harvested at the indicated times for 
HCV sequence analysis and serial passage. The whole experiment was performed twice 
with very similar results; therefore, only data from the first experiment are shown. 
 Recovery of viral quasispecies and sequence analysis. HCV was extracted with Trizol 
LS from 100uL cell culture medium harvested at the indicated times and was amplified 
with the E1 and E2 primers described above. The product was digested with Bsp119I and 
AfeI, cloned into the modified 1a/2a vector, and sequenced for either HVR1 or the entire 
E1E2 sequence. At least 18 colonies were analyzed for each time point. 
 
Infectivity determinations. Medium from cultured cells was plated on Huh7.5 cells 
growing in Lab-TekTM 8-well chamber slides (Thermo Fisher Scientific, Waltham, MA) 
and incubated at 37°C. Three days post infection, cells were fixed in 100% acetone and 
incubated for 20 min with mouse anti-core or chimpanzee 1530 anti-HCV plasma. After 
20 min, slides were rinsed and incubated with Alexa 568 anti-mouse or Alexa 488 
anti-human serum (Invitrogen) to detect core or core and E1E2 proteins respectively. 
Immunofluorescence microscopy was performed with an Axioskop 2-Plus Zeiss 
microscope and individual foci (focus forming units or FFU) were manually counted. 
 
Neutralization by anti-HVR1 antibody. LMF87 is a rabbit polyclonal antibody raised 
against a 21 amino acid peptide containing the HVR1 sequence of species A (3). 
Triplicate aliquots of 100uL each of virus in cell culture medium was mixed with control 
serum or anti-LMF87 serially diluted with complete DMEM medium, incubated at 37°C 
for 1 hr, and inoculated onto Huh7.5 cells growing in 8-well chamber slides. After 5 hrs, 
the inoculum was replaced with complete DMEM and incubation was continued for 2 
days. Cells were stained for immunofluorescence microscopy as described above and the 
foci were counted. 
 
Mutagenesis. Backbone mutations were reverted or HVR1 regions were swapped by 

















Construction of a quasispecies library. First we determined if the HCV glycoprotein 
quasispecies present in a human plasma could be faithfully reproduced as a cDNA 
population of full-length, replication-competent genomes that grew in cell culture. As a 
source of quasispecies, H77 plasma collected in 1977 from patient H during the early 
acute phase of post-transfusion hepatitis C was chosen. The E1E2 region of this genotype 
1a HCV was amplified from the plasma by RT-PCR as a single fragment which was then 
shotgun cloned into an infectious cDNA chimeric clone that expressed genotype 1a 
structural proteins in cell culture: therefore, each E1E2 combination of glycoproteins 
represented a naturally occurring, co-evolved gene pair. The cDNA mixture was 
transformed into E.coli and plasmids from seventy two colonies were sequenced to 
determine the HVR1 diversity. The HVR1 species distribution in the full-length cDNA 
clones was very similar to that obtained previously by cloning much shorter RT-PCR 
products from the same plasma (Fig. 1A, 1B). Therefore, the HVR1 quasispecies 
population of the cDNA chimera appeared to accurately mimic the quasispecies 
population in the human plasma. The sequence of the entire E1E2 region was determined 
for the two dominant species, A and B. Species A contained no consistent differences 
from H77C among 22 clones sequenced whereas, in 7 of 8 clones, species B, in addition 
to the differences in HVR1, contained a set or subset of four new amino acids outside of 
HVR1(Fig. 1C). 
 
Replacement of the dominant quasispcies during sequential passage in cell culture. 
The quasispecies of HCV chimeras was prepared by pooling the library of E.coli colonies 
on a petri dish and isolating a single preparation of plasmid DNAs. The plasmid mixture 
was batch-transcribed and the library of viral genomes was transfected into Huh7.5 cells. 
Viruses released into the medium were serially passaged three times to naïve Huh7.5 
cells. Viruses in the medium were sequenced at the time of passage (Fig. 2A). Even by 
the first time point, the complexity of the quasispecies mixture was reduced. The initial 
ratio of species A to B was maintained until the second serial passage when species B 
gained dominance. After the third serial passage, species A was no longer detected and 
100% of recovered sequences were species B. 
A repeat experiment with a slightly modified schedule of virus collection 
produced similar results. Quasispecies diversity diminished with time and the originally 
dominant species A disappeared and was replaced with species B (data not shown). Since 
the kinetics of the rise of species B to dominance suggested the presence of an adaptive 
mutation, the entire E1E2 region was sequenced. 
In both experiments, at the time species B became dominant, the region outside of the 
HVR1 contained 5 (Fig. 2B) or 6 (not shown) amino acid changes in 100% of the clones 
sequenced. Four of the changes were present in both experiments and 3 of the 4 (E431D, 
N434T, D610N) were already present in all of the genomes from the earliest time 
sequenced (Fig. 2B). In both experiments, species A genomes contained one or more 
amino acid differences also after the first passage but the level of species A still 
decreased thereafter. 
 
Effect on growth of changes within or outside of HVR1. In order to estimate the 
relative importance to growth in cell culture of the selected mutations outside of HVR1 as 
compared to the differences within HVR1, the HVR1 sequence of species A was replaced 
with that of species B and vice-versa. In both cases the backbone of the species contained 
the mutations that were present when the species was at its highest level according to 
Figure 2B. Four days post transfection, the yield of infectious virus released into the 
medium was quantified and compared to that released by the wild-type 1a/2a chimera 
(Fig. 3A, 3B). Evolved species A and B, containing their respective homologous HVR1 
region, produced yields of infectious virus that were similar to each other and about 7 
fold greater than that of wild-type. Swapping the species A and B HVR1 regions affected 
virus yield, but not in the way expected. The species A HVR1 surprisingly increased 
virus yield when in the B backbone (B-swapped) whereas the species B HVR1 decreased 
yield when in the A backbone (A-swapped). These results suggested that the changes 
outside of HVR1 were more important for growth than was the sequence of HVR1.  
The changes outside of HVR1 in evolved species B were eliminated by 
site-directed mutagenesis and the effect on virus yield was determined (Fig.4). Back 
mutation of the amino acid at 219 had little effect but back mutation of the amino acid 
pair at 431 and 434 or the amino acid at 348 or 610 decreased virus yield significantly 
(Fig.4B). These same mutations were joined by A592T in the B-evolved species from the 
second experiment .Back mutation of A592T did not decrease virus yield, whereas 
back-mutation of the amino acids at 431 and 434 or at 610 again significantly decreased 
virus yield demonstrating that they remained important in the context of a slightly 
different background (data not shown). 
 
Neutralization by anti-HVR1 is affected by sequences outside of HVR1. LMF87 
antibody raised against a peptide of species A HVR1 was thought to be specific for 
species A since treatment of the quasispecies (represented in Figure1) with this antibody 
resulted in the elimination of species A and the dominance of species B when the 
antibody-antigen mixture was tested for infectivity by inoculation into a chimpanzee (3). 
In order to determine if LMF87 antibody was specific for species A or if it cross-reacted 
with species B HVR1, evolved-species A and evolved-species B as shown in Fig. 3 were 
individually mixed with LMF87 anti-HVR1 and infectivity was quantified by a 
focus-forming assay. Species A was neutralized in a dose-dependent manner, but species 
B neutralization, although less, was significant (Fig. 5A). In order to rule out any effect 
of sequences outside the HVR1 region, the experiment was repeated with the swapped 
HVR1 species A and B shown in Fig. 3. Surprisingly, the pattern was reversed and the 
chimera containing species A HVR1 in the species B backbone was neutralized less 
efficiently than the chimera containing the species B HVR1 in the species A backbone 
(Fig. 5B). Therefore, not only does species A anti-HVR1 cross-react with species B 
HVR1, the extent of neutralization is greatly influenced by sequences outside of HVR1. 
 
Outgrowth of viruses from a mixture incompletely neutralized by LMF87. In order to 
better understand the implications of incomplete neutralization in the context of a 
quasispecies, we selected two versions of species A and two versions of species B 
(Fig.6A, B) and tested them individually for neutralization by anti-HVR1. 
In each case, species B was more resistant to neutralization than species A but inclusion 
of the D610N mutation in species B or removal of the R249G mutation from species A 
(left panels) decreased the extent of neutralization for that species (Fig.6C,D). The A and 
B species were then paired as indicated in the figure and the mixtures were incubated 
with different concentrations of LMF87 antibody and inoculated onto Huh 7.5 cells to 
permit amplification of non-neutralized virus. Forty two days later, the HVR1 sequence 
of viruses in the medium was determined. Even though each of the two species differed 
from its counterpart only by a single amino acid, the results from the two sets of cultures 
were completely opposite (Fig.6E,F). The antibody-negative controls for the two sets 
were virtually identical and species A predominated. The combination of unmodified 
species A and evolved species B resulted in outgrowth of species B (panel E) as might be 
expected since species A was more efficiently neutralized and the mutations in species B 
enhanced growth as shown in figure 4. However, the outgrowth of species A containing a 
R249G mutation (panel F) was more difficult to explain because this mutant appeared to 
be neutralized even more efficiently than the other species A used (compare panels C and 
















The complex E1E2 quasispecies circulating in a patient was reproduced as a 
chimeric quasispecies within a homogeneous HCV genomic backbone that grew in cell 
culture. This development provided an in vitro system with which to study factors 
resulting in the dominance of a particular glycoprotein species. Because tandem E1 and 
E2 genes were amplified as a single unit, the two glycoproteins encoded by each virus 
had co-evolved and, thus were expected to be functional. This assumption was confirmed 
by recovering viruses D, N, and K (Fig.2A and repeat experiment) that were present in 
low copy number in the inocula but must have replicated successfully in order not to have 
been diluted out. 
Although species A was 3-fold more abundant than species B in the transfection 
inoculum, species B eventually gained dominance suggesting that non-HVR1 mutations 
that distinguished species B from species A were candidates for adaptive mutations. And, 
indeed, as reversion-mutagenesis indicated, the mutations at I348T, E431D and/or N434T, 
and D610N all individually contributed to species B growth (Fig.4). Since E341D/N434T 
and D610N were already co-localized within viral genomes in the patient, they most 
likely enhanced growth in vivo as well as in vitro. However, it was surprising that the 
A219T mutation did not seem to enhance growth in cell culture since it was detected in 
early passages in 100% of the species B clones in two independent experiments (Fig. 2 
and repeat experiment ), consistent with its conveying a growth advantage. The fact that 5 
of the 8 species B clones isolated from the patient already contained this mutation 
suggested it may have offered a selective advantage in vivo but was neutral in vitro and, 
therefore, was passively retained. Comparative release of virus into the medium by 
species A-evolved and species B-evolved viruses containing the mutations present at 
their peak prevalence in cell culture suggested that the I348S mutation in species A, like 
the I348T mutation in species B, was adaptive since growth of species A-evolved was 
significantly more than for the wild-type 1a/2a control which differed only in lacking this 
mutation (Fig 3A and B). However, this mutation was not detected in the second 
experiment and was never present in 100% of the A species clones throughout the first 
experiment which may explain why species B dominated in the long term even though 
species A-evolved and B-evolved viruses released similar amounts of progeny virus into 
the medium in the short term (Fig 3). Note that since the data in figure 3 were collected 4 
days post transfection, they reflect the rate of replication, assembly and egress, but not 
infection. Therefore, the A-evolved virus, as has been shown for other HCV mutants (11), 
might have been able to exit, but not to enter cells efficiently and thus not spread as 
rapidly as the B-evolved virus. 
The fact that non-HVR1 mutations in E1 or E2 enhanced growth in cell culture 
was not surprising since enhancing mutations have been demonstrated for many HCV 
variants. In contrast, it was surprising that these mutations had such a profound and 
non-predictable effect when paired with the heterologous HVR1. Even though both 
evolved-species A and B viruses grew to similar extents, swapping the HVR1 regions 
from one background to the other led to decreased growth of the chimeric virus in one 
case (A-swapped) and increased growth in the other (B-Swapped) (Fig 3). 
Even more remarkable was the effect that these non-HVR1 mutations had on virus 
neutralization by the LMF87 anti-HVR1 antibody. The fact that LMF87 antibody 
neutralized species A more efficiently than species B (Fig 5A) was understandable since 
the antibody was raised against a peptide with an amino acid sequence that perfectly 
matched the HVR1 of species A and differed from that of species B in 4 of 21 positions 
(3). The hierarchy of neutralization was reversed when the HVR1 regions were swapped 
between species A and B such that the virus containing the homologous species A HVR1 
region was neutralized less efficiently than that containing the cross-reactive species B 
sequence. These data suggest that although the HVR1 occupies the terminus of the E2 
protein, it does not function as an independent unit: the neutralization data comparing 
authentic E2 and HVR1-swapped E2 suggest that access to the relevant epitope(s) or 
avidity for the epitope(s) is greatly affected in unpredictable ways by mutations in other 
parts of the molecule. Recently,HVR1 was proposed to have different functional roles in 
different isolates (9). Reverse genetic studies with JFH1-based recombinant viruses of 
genotypes 1-6 demonstrated that deletion of HVR1 from 3 of the 8 recombinants had 
little effect on virus spread or infectivity in vitro ; in contrast, deletion of HVR1 from 5 of 
the 8 recombinants produced viruses that were severely attenuated but, with one 
exception, could be rescued by acquisition of adaptive mutations in E1 or in the 
remaining portion of E2 (9). 
 
The confusing data from experiments examining outgrowth of a virus 
quasispecies following incomplete neutralization (Fig.6E,F) emphasize that dominance 
reflects a delicate balance between the initial concentration of viable virus 
(non-neutralized) and the fitness of the virus and that seemingly small differences can 
determine which species ultimately achieves dominance. 
In summary, it is possible to create a quasispecies of HCV glycoproteins that represent a 
natural population and that can be analyzed in toto or in parts in an in vitro cell culture 
system. Although only genotype 1a was examined in the present study, this strategy 
should be applicable to almost any HCV strain for which a cDNA clone encoding a cell 
culture-adapted virus of that particular genotype exists. Gottwein and colleagues ( 6) 
have already developed cDNA clones of cell culture-adapted viruses for the remaining 
genotypes 2-7 which, just like the genotype 1a clone used here, encode JFH1-based 
recombinant viruses expressing Core/E1/E2/p7/NS2 of each genotype respectively. 
Therefore, it should be straightforward to insert unique restriction sites abutting the E1E2 
region to construct a cassette  which can be used to generate an E1E2 quasispecies in the 
background of the homologous structural proteins. The generation of a representative 
glycoprotein quasipecies is another step toward development of a cell culture model that 
more closely reproduces the complexity of the in vivo situation.  It provides a promising 
system to study virus replication and dynamics of HCV replication and neutralization. 
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Fig. 1. Quasispecies analysis of shotgunned clones. (A) The HVR1 amino acid 
sequence and the number of clones encoding that sequence are shown compared to the 
sequence of H77C. (B) Comparison of HVR1 sequences in shotgunned clones (solid 
bars) with those found by Farci et al. (open bars) (3). Species H through N were not 
detected in the previous study. (C) The predominant amino acid sequences for the entire 
E1E2 region of species A and B are shown as differences from H77C. The original amino 
acid is followed by the amino acid position in H77C and the new amino acid: percent of 
clones with that amino acid is given in parentheses. S-I-F-T is N391S, T396I, L399F and 
V400T in HVR1 of species B. 
 
Fig. 2. Evolution of HVR1 and E1E2 quasispecies during long term culture.(A) Huh7.5 
cells were transfected with the quasispecies chimeras shown in Fig. 1A.  The 
quasispecies of viruses released into the medium at day 18 was sequenced and used to 
infect naïve Huh7.5 cells. This step was repeated at days 50 and 65 and the final sequence 
was obtained on the day 75 sample. Species A, B, D and N were identified in the original 
inoculum and expressed as percent of viruses sequenced: species without a letter 
designation were not detected in the inoculum(B) Consensus sequence of E1E2 of species 
A and B chimeras. See Fig. 1 legend for details. S-I-F-T are mutations in HVR1 of 
species B. 
 
Fig. 3.  Effects of HVR1 sequence and non-HVR1 mutations on growth in Huh7.5 cells 
(A) Diagram of “evolved” species showing mutations that were selected during passage 
and were present in the backbone of the majority of genomes at the time of peak virus 
titer and diagram of “swapped” species in which the HVR1 regions of species A and B 
were swapped by PCR mutagenesis. Species A and B sequences are shown in black and 
white respectively. (B) Infectious viruses (FFU) released into the medium at day 4 
posttransfection were quantified by a focus forming assay. The wild-type 1a/2a chimera 
served as a standard and was assigned a value of 1. Species A and B regions are shown in 
black and white respectively. 
 
Fig. 4. Effect of backbone mutations on growth of species B.(A) Diagram of backbone 
mutations present in the dominant B species at peak titer in the two experiments. (B) 
Ratio of released infectious test virus compared to wild-type. Wild-type virus 




Fig. 5. Neutralization of species A and B and “swapped” chimeras by rabbit antibody 
LMF87 raised against the HVR1 peptide of species A. (A) Huh7.5 cells were transfected 
with RNA transcripts from species A (black bar) or B (white bar) and viruses in the 
medium at day 4 posttransfection were mixed with dilutions of LMF87 or control serum 
and the number of infectious viruses was determined in a focus forming assay. % 
neutralization = 1- (FFU in LMF87 sample /FFU in control sample) X 100. (B) HVR1 
regions of species A (black) and species B (white) were swapped by PCR mutagenesis 
and neutralization by LMF87 was determined as for Fig.5A. 
 
Fig. 6. Effect of backbone mutations on virus outgrowth following neutralization by 
LMF87 antibody raised against the HVR1 peptide of species A. Panels A and B: 
diagrams of species A (black) and B (white) pairs tested; Panels C and D: respective % 
neutralization by LMF87; Panels E and F: a 50:50 mixture of species A and B as 
diagramed above was incubated with control serum or with dilutions of LMF87 
anti-HVR1 prior to inoculation onto Huh7.5 cells. After 4 days of culture, the HVR1 of 
viruses in the medium was sequenced to determine the species distribution. Species 
A(black); species B(white); new mutation in HVR1(hatched). 
 
 
 
  
 
 
 
 
 
 






